Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
Karmiris K, et al. Among authors: vermeire s.
Gastroenterology. 2009 Nov;137(5):1628-40. doi: 10.1053/j.gastro.2009.07.062. Epub 2009 Aug 5.
Gastroenterology. 2009.
PMID: 19664627